Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial


Por: Juanes, A, Garin, N, Mangues, MA, Herrera, S, Puig, M, Faus, MJ, Baena, MI

Publicada: 1 sep 2018
Resumen:
Background The resolution of potential drug-related problems is a priority of pharmaceutical care programmes. Objectives To assess the clinical impact on drug-related negative outcomes of a pharmaceutical care programme focusing on the resolution of potential drug-related problems, initiated in the emergency department for patients with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD). Methods Controlled trials, in which older adults (65 years) receiving four or more medications admitted to the emergency department for 12hours for worsening of HF and/or COPD were randomised (1:1) to either a pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department (intervention group (IG)) or standard care (control group). Comparisons between the groups were made for the proportion of patients with drug-related negative outcomes, number of drug-related negative outcomes per patient, mean stay, patients readmitted within 180 days and 180-day mortality. Results 118 patients were included, 59 in each group. Fewer patients in the IG had drug-related negative outcomes (37 (62.7%) vs 47 (79.7%) in the control group (p=0.042)). Fewer drug-related negative outcomes per patient occurred in the IG (56 (0.95 per patient) vs 85 (1.44 per patient) in the control group (p=0.01)). The mean stay was similar between groups (194.7hours in the IG vs 242.5hours in the control group (p=0.186)). No difference in revisits within 180 days was found (32 (54.24%) in the IG vs 22 (37.3%) in the control group (p=0.065)). 180-Day mortality was detected in 11 (18.6%) patients in the IG compared with 13 (22%) in the control group (p=0.647). Conclusion A pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department has a favourable clinical impact, as it reduces the number and prevalence of drug-related negative outcomes. No difference was found in other outcome variables. Trial registration number NCT02368548.

Filiaciones:
Juanes, A:
 Hosp Santa Creu & Sant Pau, Dept Pharm, Barcelona, Spain

Garin, N:
 Hosp Santa Creu & Sant Pau, Dept Pharm, Barcelona, Spain

 Inst Salud Carlos III, Ctr Invest Biomd Red Salud Mental, CIBERSAM, Madrid, Spain

Mangues, MA:
 Hosp Santa Creu & Sant Pau, Dept Pharm, Barcelona, Spain

 CIBER BBN, Barcelona, Spain

Herrera, S:
 Hosp Santa Creu & Sant Pau, Emergency Dept, Barcelona, Spain

Puig, M:
 Hosp Santa Creu & Sant Pau, Emergency Dept, Barcelona, Spain

Faus, MJ:
 Univ Granada, Pharmaceut Care Res Grp, Granada, Spain

Baena, MI:
 Univ Granada, Pharmaceut Care Res Grp, Granada, Spain
ISSN: 20479956





EUROPEAN JOURNAL OF HOSPITAL PHARMACY
Editorial
BMJ PUBLISHING GROUP, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 25 Número: 5
Páginas: 274-280
WOS Id: 000443600400009
ID de PubMed: 31157039
imagen Green Published, Bronze

MÉTRICAS